Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways

BACKGROUND: Pirfenidone (PFD) is effective for pulmonary fibrosis (PF), but its action mechanism has not been fully explained. This study explored the signaling pathways involved in anti-fibrosis role of PFD, thus laying a foundation for clinical application. METHODS: Pulmonary fibrosis mice models...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Qun, Wang, Jianjun, Xu, Changqing, Huang, Xuqing, Ruan, Zhaoyang, Dai, Yifan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245944/
https://www.ncbi.nlm.nih.gov/pubmed/32448163
http://dx.doi.org/10.1186/s10020-020-00173-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245944/
https://www.ncbi.nlm.nih.gov/pubmed/32448163
http://dx.doi.org/10.1186/s10020-020-00173-3

Ejemplares similares